Zhang L - Search Results

1

Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment.

Xue C, Hong S, Li N, Feng W, Jia J, Peng J, Lin D, Cao X, Wang S, Zhang W, Zhang H, Dong W, Zhang L. Xue C, et al. Among authors: zhang l, zhang w, zhang h. Sci Rep. 2015 Jul 28;5:10648. doi: 10.1038/srep10648. Sci Rep. 2015. PMID: 26216071 Free PMC article. Clinical Trial.

2

Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer.

Zhou T, Zhan J, Hong S, Hu Z, Fang W, Qin T, Ma Y, Yang Y, He X, Zhao Y, Huang Y, Zhao H, Zhang L. Zhou T, et al. Among authors: zhang l. Sci Rep. 2015 Jun 18;5:10481. doi: 10.1038/srep10481. Sci Rep. 2015. PMID: 26084991 Free PMC article.

3

QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC.

Yang YP, Ma YX, Huang Y, Zhao YY, Fang WF, Hong SD, Tian Y, Xue C, Sheng J, Zhang L. Yang YP, et al. Among authors: zhang l. Sci Rep. 2015 Jul 3;5:11934. doi: 10.1038/srep11934. Sci Rep. 2015. PMID: 26137916 Free PMC article. Clinical Trial.

4

The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis.

Zhang Y, Fang W, Yan Y, Wang M, Kang S, Sheng J, Zhan J, Chen N, Hong S, Yang Y, Ma Y, He D, Qin T, Zhou T, Tang Y, He X, Liang W, Zhang L. Zhang Y, et al. Among authors: zhang l. Med Oncol. 2015 Mar;32(3):61. doi: 10.1007/s12032-015-0489-y. Epub 2015 Feb 8. Med Oncol. 2015. PMID: 25663066

5

Trends in incidence and associated risk factors of suicide mortality in patients with non-small cell lung cancer.

Zhou H, Xian W, Zhang Y, Chen G, Zhao S, Chen X, Zhang Z, Shen J, Hong S, Huang Y, Zhang L. Zhou H, et al. Among authors: zhang l, zhang z, zhang y. Cancer Med. 2018 Aug;7(8):4146-4155. doi: 10.1002/cam4.1656. Epub 2018 Jul 3. Cancer Med. 2018. PMID: 29971970 Free PMC article.

6

Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.

Zhao S, Zhang Z, Zhang Y, Hong S, Zhou T, Yang Y, Fang W, Zhao H, Zhang L. Zhao S, et al. Among authors: zhang l, zhang z, zhang y. Int J Cancer. 2019 Jun 1;144(11):2854-2866. doi: 10.1002/ijc.31995. Epub 2019 Jan 7. Int J Cancer. 2019. PMID: 30430561

7

Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.

Hong S, Zhang Y, Yu G, Peng P, Peng J, Jia J, Wu X, Huang Y, Yang Y, Lin Q, Xi X, Xu M, Chen D, Lu X, Wang R, Cao X, Chen X, Lin Z, Xiong J, Lin Q, Xie C, Li Z, Pan J, Li J, Wu S, Lian Y, Yang Q, Zhao C, Fang W, Zhang L. Hong S, et al. Among authors: zhang l, zhang y. J Clin Oncol. 2021 Oct 10;39(29):3273-3282. doi: 10.1200/JCO.21.00396. Epub 2021 Aug 11. J Clin Oncol. 2021. PMID: 34379443 Free PMC article. Clinical Trial.

8

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.

Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y, Chen N, Zhan J, He X, Qin T, Li G, Tang W, Peng P, Zhang L. Tang Y, et al. Among authors: zhang l, zhang y. Oncotarget. 2015 Jun 10;6(16):14209-19. doi: 10.18632/oncotarget.3694. Oncotarget. 2015. PMID: 25895031 Free PMC article.

9

The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysis.

Sheng J, Yang Y, Ma Y, Yang B, Zhang Y, Kang S, Zhou T, Hong S, Qin T, Hu Z, Fang W, Huang Y, Zhang L. Sheng J, et al. Among authors: zhang l, zhang y. PLoS One. 2015 Jun 2;10(6):e0127306. doi: 10.1371/journal.pone.0127306. eCollection 2015. PLoS One. 2015. PMID: 26034985 Free PMC article.

10

The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations.

Xin S, Zhao Y, Wang X, Huang Y, Zhang J, Guo Y, Li J, Li H, Ma Y, Chen L, Hu Z, Huang M, Zhang L. Xin S, et al. Among authors: zhang l, zhang j. Sci Rep. 2015 Jul 31;5:12675. doi: 10.1038/srep12675. Sci Rep. 2015. PMID: 26228025 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

132,712 results

Search Page

Filters